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Cyclotides are plant derived, cystine-knot stabilized peptides characterized by their
natural abundance, sequence variability and structural plasticity. They are abundantly
expressed in Rubiaceae, Psychotrieae in particular. Previously the cyclotide kalata B7
was identified to modulate the human oxytocin and vasopressin G protein-coupled
receptors (GPCRs), providing molecular validation of the plants’ uterotonic properties
and further establishing cyclotides as valuable source for GPCR ligand design. In this
study we screened a cyclotide extract derived from the root powder of the South
American medicinal plant ipecac (Carapichea ipecacuanha) for its GPCR modulating
activity of the corticotropin-releasing factor type 1 receptor (CRF1R). We identified and
characterized seven novel cyclotides. One cyclotide, caripe 8, isolated from the most
active fraction, was further analyzed and found to antagonize the CRF1R. A nanomolar
concentration of this cyclotide (260 nM) reduced CRF potency by ∼4.5-fold. In contrast,
caripe 8 did not inhibit forskolin-, or vasopressin-stimulated cAMP responses at the
vasopressin V2 receptor, suggesting a CRF1R-specific mode-of-action. These results
in conjunction with our previous findings establish cyclotides as modulators of both
classes A and B GPCRs. Given the diversity of cyclotides, our data point to other
cyclotide-GPCR interactions as potentially important sources of drug-like molecules.
Keywords: plant peptides, circular peptide, pharmacognosy, ipecac, GPCR, corticotropin-releasing factor
INTRODUCTION
Historically plants have been a rich source for drug discovery. For example salicylic acid, one of
the most well-known antipyretic, anti-inflammatory and analgesic drugs, was originally derived
from willow bark (Salix alba) (Aronson, 2013). Similarly, the discovery of artemisinin, a highly
effective compound against the Malaria parasite was first isolated from Artemisia annua (Tu, 2011),
led to the award of the Nobel Prize in Physiology and Medicine in 2015 (Efferth et al., 2015).
Such discoveries have commonly involved small molecules. However, plant peptides are gaining
consideration for new opportunities in drug discovery and development (Craik et al., 2013).
Plants produce a variety of peptides that comprise hormones for cellular signaling, secretory
peptides for interspecies communication, and defense peptides against microbes, herbivores
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and pests (Marmiroli and Maestri, 2014). An interesting group
of plant-derived peptides with applications in drug discovery
are cyclotides, which belong to the large class of ribosomally
synthesized and post-translationally modified peptides (Arnison
et al., 2013). Cyclotides are disulfide-rich peptides (∼30 amino
acids) that contain a head-to-tail cyclized backbone and six
conserved cysteine residues forming three knotted disulfide
bonds. This unique topology, known as the cyclic cystine-knot
motif (Craik et al., 1999), confers them a tightly packed three-
dimensional fold and makes them notably stable against thermal,
chemical, and enzymatic degradation (Colgrave and Craik, 2004).
In addition, cyclotides exhibit an unprecedented variability and
natural abundance: a single species can express over 150 different
cyclotides (Hellinger et al., 2015b; Serra et al., 2016). In total,
the number of unique cyclotides to be discovered in plants
has been estimated to exceed 100,000 (Hellinger et al., 2015b),
hence, making this group of peptides one of the most abundant
and diverse of plant origin (Gruber et al., 2008; Burman et al.,
2015). Moreover, due to their stability and structural plasticity
(Clark et al., 2006), cyclotides have attracted attention as potential
frameworks for peptide-based drug design and pharmaceutical
applications (Craik and Du, 2017).
Besides the natural role of cyclotides as plant defense
agents (Gruber et al., 2007; Craik, 2012), they exhibit a
broad range of pharmaceutically relevant activities including
cytotoxicity (Burman et al., 2011), uterotonic (Gran et al., 2008;
Gruber and O’Brien, 2011), anticancer (Esmaeili et al., 2016),
anti-HIV (Wang et al., 2007) and immunosuppressive properties
(Gründemann et al., 2012, 2013; Hellinger et al., 2014; Thell et al.,
2016). Furthermore, together with the discovery of a cyclotide
agonist of the human oxytocin and vasopressin 1a receptors,
cyclotides can be utilized as natural templates for G protein-
coupled receptor (GPCR) ligand design (Koehbach et al., 2013b).
Cyclotides have been isolated and characterized from
different flowering plant species of the Rubiaceae, Violaceae,
Cucurbitaceae, Fabaceae, Solanaceae, and Poaceae families
[summarized in (Hellinger et al., 2015b; Koehbach and Clark,
2016)]. Inspired by their original discovery from Oldenlandia
affinis, the Rubiaceae family, has been a major focus for
studying the diversity and distribution of cyclotides (Gruber
et al., 2008; Gruber, 2010; Koehbach et al., 2013a). In particular
the genus Psychotria sensu lato (s.l.) provides enormous
resource for the discovery of pharmacologically active cyclotides.
For example, purification of the cyclotide cyclopsychotride A
from an extract of Psychotria longipes (now reclassified as
P. vellosiana), identified a blocker of neurotensin 1 receptor
signaling (Witherup et al., 1994), another representative of
the GPCR family. Previously we discovered cyclotides in
P. ipecacuanha (Brot.) [=Carapichea ipecacuanha (Brot.)] using
an innovative transcriptome-mining approach (Koehbach et al.,
2013a). A herbal preparation of the root extract of C. ipecacuanha
is commonly known as ‘syrup of ipecac,’ which has a long
history in traditional medicine and has been used in Western
clinical practice until the late 20th century for its properties
as emetic and expectorant agent. It is well documented that
the major alkaloids emetine and cephaeline are causing these
effects (Lee, 2008). However, hitherto there are no reports of
pharmacological activities of cyclotides derived from the root
extract of ipecac.
Knowing that cyclotides are able to modulate GPCR signaling
of representative class A receptors [i.e., the oxytocin- (Koehbach
et al., 2013b), vasopressin V1a- (Koehbach et al., 2013b)
and neurotensin 1 receptors (Witherup et al., 1994)] and
that they are abundantly expressed in plants of the genus
Psychotria, the present study aimed to expand our exploration
of cyclotides as ligands of other GPCRs. In particular, we
focused on identifying novel cyclotides present in C. ipecacuanha
and investigation of their properties to modulate signaling
of the corticotropin-releasing factor type 1 receptor (CRF1R)
using a bioassay-guided fractionation approach combined with
pharmacological and structural analysis. The CRF1R is a
prototypical class B GPCR, and together with its endogenous
ligand CRF (a peptide hormone containing 41 amino acids),
regulates the hypothalamic-pituitary-adrenal axis that provokes
cortisol release and coordinates the endocrine response to stress
behaviors in the central nervous system (Gutman et al., 2003).
The CRF peptide and its receptor are also involved in the
response of the gut to stress-related colonic functions. Hence
CRF1R signaling is thought to be an important therapeutic target
of gut-related stress disorders, such as irritable bowel syndrome
(Tache et al., 2004), as well as to treat anxiety, depression and drug
addiction (Zorrilla and Koob, 2010; Logrip et al., 2011; Navarro
et al., 2015).
Here, we analyzed a cyclotide-rich root extract of
C. ipecacuanha by reversed-phase high-performance liquid
chromatography (RP-HPLC) and matrix-assisted laser
desorption ionization time-of-flight (MALDI-TOF) mass
spectrometry (MS) utilizing chemical derivatization and
enzymatic digest. Using a robust, cell-based luciferase reporter
assay we isolated novel cyclotides that antagonized the CRF1R,
which has been confirmed by quantitative second messenger
analysis. The structures of these cyclotides were elucidated
by combining de novo peptide sequencing and transcriptome
analysis. This is to our knowledge the first report demonstrating
cyclotides as modulators of class B GPCR signaling and
further advances our understanding of their diverse molecular
mechanism of action.
RESULTS
Preparation and Analysis of
Cyclotide-Containing Plant Extracts
Based on previous methods for cyclotide extraction and
identification (Hashempour et al., 2013; Koehbach et al., 2013a;
Hellinger et al., 2015a), we isolated and characterized cyclotides
from ipecac root (Figure 1A) powder (C. ipecacuanha) with the
aims to expand our knowledge of cyclotide sequence diversity
and to investigate their modulating effects on signaling of
class B GPCRs. The initial aqueous root extract of ipecac was
prepared by maceration; this extract was then pre-purified by C18
solid-phase extraction to remove polar plant constituents. This
resulting ‘ipecac extract’ was analyzed by RP-HPLC to confirm
the presence of absorbance signals across a linear acetonitrile
Frontiers in Pharmacology | www.frontiersin.org 2 September 2017 | Volume 8 | Article 616
fphar-08-00616 September 21, 2017 Time: 16:33 # 3
Fahradpour et al. Isolation and GPCR Pharmacology of Ipecac Cyclotides
FIGURE 1 | Analytical profile of ipecac cyclotide extract. (A) Image of a representative Carapichea ipecacuanha root [photograph by courtesy and with permission of
Orlando Vargas Ramírez (Vargas, 2017), Organization for Tropical Studies, Costa Rica]. (B) Analytical reversed-phase liquid chromatography (RP-HPLC) of crude
cyclotide-enriched extract of C. ipecacuanha, with magnification of cyclotide fractions (inset), performed using linear gradients as described in the section “Materials
and Methods.” (C,D) Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectra of (C) the hydrophobic cyclotide-rich fraction and (D) the
hydrophilic non-cyclotide containing fraction from the crude extract. (E) Inhibition of human CRF-induced CRE-specific luciferase activity by ipecac cyclotide
extracts. The data presented are mean ± SD of five separate experiments performed in triplicate. (F) The ipecac extract inhibits human CRF response in a
concentration-dependent manner with an IC50 of 2.0 µg mL−1. Masses labeled in the spectra refer to monoisotopic [M+H]+.
gradient (Figure 1B). Due to the hydrophobic surface properties
of cyclotides, they elute late in reversed-phase chromatography.
Hence we manually collected the early- (hydrophilic) and late-
eluting (hydrophobic) fractions to analyze the presence of
cyclotides in the ipecac extract via MALDI-TOF MS. As expected,
mass signals characteristic for the presence of cyclotides were
identified within the molecular weight range of 2500–4000 Da
(Figure 1C), but were absent on the more hydrophilic fraction
of the extract (Figure 1D). Given our interest in the discovery of
novel GPCR-modulating compounds, we measured effects of the
ipecac extract on CRF1 receptor signaling.
Modulating Effect of Ipecac Extract on
CRF1 Receptor Signaling
The ipecac extract was tested for its modulating effect on CRF1R
signaling using a cell-based luciferase reporter assay. HEK293
cells transiently transfected with an C-terminally GFP-tagged
human CRF1R and a luciferase-coupled cAMP response element
(CRE) were stimulated with varying concentrations of ipecac
extract (0.01–50 µg mL−1) in the presence and absence of
50 nM endogenous corticotropin-releasing factor (CRF) ligand.
Concentration-dependent inhibition of receptor signaling was
determined by measuring luciferase induction and accounting
for the fluorescence of receptor-positive cells. The amount of
luminescence of the control samples incubated with hormone
alone was defined as 100% efficacy (Figure 1E). The inhibitory
potency of the corresponding cyclotide-containing ipecac extract
was measured and normalized relative to the efficacy of the
control. The ipecac extract exhibited CRF-stimulated CRF1R
inhibition in a concentration-dependent manner, whereas the
extract only did not induce any effect (Figure 1E). The inhibitory
potency of the ipecac extract to antagonize CRF1R signaling
was determined as half-maximal concentration (IC50) as 2.0 µg
mL−1 (Figure 1F). Assuming that the ipecac extract contained
cyclotides, it was reasonable to further determine the typical
structural properties of these peptides, i.e., the presence of six
cysteines and a circular peptide backbone.
Identification of Cyclotides in the
Cyclotide-Enriched Ipecac Fraction
Given the antagonism of CRF1R-mediated luciferase activity by
the ipecac extract, we sought to identify the cyclotides present
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in the extract. The ipecac extract was subject to bio-chemical
derivatization by thiol-reduction, carbamidomethylation and
endopeptidase treatment, using dithiothreitol, iodoacetamide,
and endoproteinase (endo-)GluC, respectively. Cyclotides
generally, and particularly caripe cyclotides, contain a single
conserved glutamic acid residue (Koehbach et al., 2013a).
Hence, digestion with endo-GluC is a valuable tool for analyzing
cyclotides. It was clear that the mass signals (e.g., 3254.3, 3238.4,
and 3302.3 Da) in the unmodified extract (Figure 2A) shifted by
348± 0.1 Da (i.e., 3602.4, 3586.4, and 3650.3 Da) after reduction
and alkylation (Figure 2B), characteristic of peptides containing
six thiol-oxidized cysteine residues. In addition, the masses of
these peptide signals increased by another 18 Da (i.e., 3620.4,
3604.4, and 3668.3 Da) after enzymatic digest with endo-GluC
(Figure 2C), corresponding to the addition of a H2O molecule,
typical for the enzymatic ring-opening of a backbone cyclized
peptide.
Bioactivity-Guided Fractionation of
Cyclotide-Containing Ipecac Extract
After confirming the presence of cyclotides in the ipecac extract,
we aimed to isolate the cyclotides responsible for CRF1R
antagonism using a bioassay-guided fraction approach. Despite
the presence of cyclotide in the ipecac extract, the HPLC
chromatogram of the ipecac extract (Figure 3A) indicated the
presence of early-eluting, hydrophilic non-cyclotide compounds.
To remove these unwanted impurities and for improvement of
preparative cyclotide fractionation yield, the ipecac extract was
pre-fractionated by solid-phase extraction as explained in the
section “Materials and Methods” (Figures 3A,B). The resulting
cyclotide-enriched ipecac fraction was subject to fractionation
by preparative HPLC, and manual collection of seven cyclotide
fractions as indicated in alphabetical order (A–G) in the
chromatograms (Figure 3B). All fractions were analyzed by
analytical HPLC and MALDI-TOF MS. Fractions A and B
only contained trace amounts of cyclotides, whereas fractions
E, F, and G each contained individual cyclotides with high
purity (Supplementary Figure 1). Fractions C and D were
determined to contain at least two cyclotides (Figures 4B,C
and Supplementary Figure 1). All fractions were examined
with the luciferase activity assay, as described earlier, and
tested for agonism/antagonism at the CRF1R. We tested two
concentrations per fraction (10 and 50 µg mL−1) in the absence
and presence of CRF ligand (Figure 3C). None of the fractions
mediated any changes in luciferase signal when applied to the
CRF1R cells alone. On the other hand all fractions A–G of
the cyclotide-enriched ipecac fraction were capable of inhibiting
the CRF-stimulated (50 nM) luciferase induction, suggesting
that the cyclotides antagonize, but do not activate the CRF1R.
Analyzing the percentage of inhibition, fraction F appeared to
be the most effective antagonist, which inhibited CRF-induced
luciferase signal by 37.6 and 98.2% at 10 and 50 µg mL−1,
respectively. These results suggested that the ipecac extract, and
the cyclotide-enriched fraction, respectively, contain cyclotides
that inhibit the CRF1R with varying inhibitory potential. It was
therefore of major importance to characterize these cyclotides
at a molecular level, by further purification and amino acid
sequencing.
Purification of Co-eluting Cyclotides
Analytical RP-HPLC and MALDI-TOF MS analyses confirmed
the purity of all fractions except C and D (Supplementary
Figure 1). MALDI-TOF MS spectra of the latter two fractions
indicated the presence of multiple mass signals corresponding
to at least two cyclotides in each fraction. Since preparative scale
RP-HPLC system was not able to discriminate and resolve these
co-eluting peptides (Figure 4A), we utilized a semi-preparative
method to isolate these Carapichea ipecacuanha (caripe)
cyclotides to purity. Fraction C eluted between 78–83 min
and was collected as two sub-fractions C1 (78–79 min) and
C2 (80–82 min) (Figure 4B). MALDI-TOF MS spectra and
analytical HPLC analysis of each fraction confirmed their high
purity, and indicated the presence of a single, distinct cyclotide
in each fraction, caripe 10 and caripe 11, respectively (Figure 4B
and Supplementary Figure 1). The semi-preparative HPLC
chromatogram of fraction D contained a broad peak eluting
between 83 and 87 min, which was collected as two sub-fractions
D1 (83–84 min) and D2 (85–86 min) (Figure 4C). MALDI-TOF
MS spectra and analytical HPLC revealed the separation of
distinct HPLC peaks in fractions D1 and D2 that were later
sequenced as psyle E and caripe 12, respectively (Figure 4C and
Supplementary Figure 1).
De Novo Sequencing of Caripe
Cyclotides
Amino acid sequences of purified cyclotides derived from
fractions C-G (Figure 3B and Supplementary Figure 1)
were obtained using an optimized MALDI-based peptidomics
approach, termed ‘sequence fragment assembly’ (Hashempour
et al., 2013). The trace amounts of cyclotides in fractions A
and B precluded their inclusion for sequencing. The overall
workflow is illustrated for caripe 8 (Figure 5) and shown
for other de novo sequenced cyclotides in the Supplementary
Figures 2–7. First, the purified, native cyclotides (Figures 5A,B)
were chemically modified to yield S-carbamidomethylation of
cysteines. This included the reduction of disulfide bonds with
dithiothreitol, and the alkylation of reduced sulfhydryl groups
with iodoacetamide, which yielded a mass shift of 348.1 Da
(Figure 5C), indicative of the presence of six cysteine residues
(as mentioned previously). Afterward, the fully reduced and
alkylated peptides were digested with a single enzyme, i.e., trypsin
or endo-GluC to produce linear peptide chains amenable to
fragmentation by MS/MS. The resulting spectra were analyzed
manually by allocating N-terminal b- and C-terminal y-ions
(Figures 5D,E). Due to the presence of only one conserved
glutamic acid residue in the cyclotide sequence, an endo-GluC
digest will usually provide a complete C-N ion series of
the linearized precursor ion (caripe 8, 3604.8 Da). On the
other hand, tryptic digests of cyclotides derived from HPLC
fractionation often results in undistinguishable fragmentation
patterns due to multiple enzyme cleavage sites (Arg and Lys),
and hence multiple (and sometimes very small fragments, or
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FIGURE 2 | MALDI-TOF mass spectrometry (MS) of crude and chemically modified cyclotide-enriched extract. Mass spectra of (A) unmodified extract, (B) reduced
and alkylated crude extract (red.+alk.) using dithiothreitol and iodoacetamide, and (C) endo-GluC digested extract are shown. Masses labeled in the spectra refer to
monoisotopic [M+H]+ and cyclotides are labeled according to Table 1. Using this analysis workflow, circular peptides containing six cysteines typically exhibit a
mass shift of +348 Da (red.+alk.) and +366 Da (endo-GluC).
FIGURE 3 | Purification and bioassay-guided fractionation of ipecac cyclotides. Preparative RP-HPLC A214 chromatograms of crude extract of C. ipecacuanha (A)
before and (B) after cyclotide-enrichment via solid-phase extraction. (B, inset) shows the elution profile of the main cyclotide fractions A–G. (C) Inhibition of human
CRF1R by cyclotide fractions (A–G), in the absence (left panel) and presence of the endogenous agonist, CRF, (50 nM; right panel). Data were normalized to the
response of CRF (50 nM) alone. Cyclotides were dissolved in ddH2O for luciferase assays and tested at concentrations of 10 (solid bars) and 50 (dotted bars) µg
mL−1 for their ability to inhibit CRF (black bars) signaling. Data shown are mean ± SD of two experiments.
single amino acids) (Hashempour et al., 2013) (for caripe 8 only
the largest precursor with 2770.3 Da provided useful sequence
information, Figure 5E). To overcome this problem in de
novo cyclotide sequencing, single and double digests combining
trypsin, endo-GluC and chymotrypsin were applied to generate
smaller fragments with distinct molecular weight (Figure 5F).
By combining the annotated sequence information derived from
the molecular weight of fragments and alignment with the
assigned endo-GluC ion series it was possible to assemble the full
cyclotide sequence. In the example of caripe 8, the combination
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FIGURE 4 | Analysis and purification of co-eluting Carapichea cyclotides. (A) Preparative RP-HPLC of cyclotide-enriched fraction of C. ipecacuanha shown in the
cyclotide-eluting region of the chromatogram. Cyclotide fractions A–G are indicated. Co-eluting cyclotides in fraction C and D were further analyzed and purified.
(B,C) The two cyclotides in (B) fraction C (caripe 10 and caripe 11) and (C) fraction D (caripe 12 and psyle E) were purified by semi-preparative RP-HPLC (left panel)
and characterized by analytical RP-HPLC (A214 trace indicating elution times) (middle panel) and MALDI-TOF MS (right panel). Masses labeled in the spectra refer to
monoisotopic [M+H]+.
of trypsin/chymotrypsin (1338.5, 1450.6, and 1917.8 Da) and
endo-GluC/chymotrypsin provided each three distinct fragments
(1001.3, 2129.2, and 2622.5 Da) (Figure 5F). Each full length
sequence was generated by alignment of the sequenced endo-
GluC and tryptic ion series, with the annotated fragments
of the trypsin/chymotrypsin and endo-GluC/chymotrypsin
digest. Finally, sequences were confirmed by automated ion
fragmentation analysis, chymotrypsin fragmentation pattern,
sequence homology, and amino acid analysis (see Materials
and Methods section). Applying this approach for sequencing
of cyclotides isolated from ipecac fraction A–G led to the
identification of seven cyclotides, four of which (caripe 10, 11,
12, and 13) were previously unknown sequences (Table 1). Of
the three known cyclotides, two cyclotides, caripe 7 and 8,
were only characterized at a transcriptome level by tBLASTn
(Wang et al., 2008) mining of the 1kp dataset (Koehbach et al.,
2013a), and their molecular structure was here for the first
time confirmed at a peptide level (Table 1). The third cyclotide,
psyle E has been previously isolated from P. leptothyrsa (Gerlach
et al., 2010), possibly indicative of the evolutionary relationship
between P. leptothyrsa and C. ipecacuanha.
Sequence analysis of purified C. ipecacuanha cyclotides
revealed the existence of the conserved six cysteine residues,
the conserved glutamic acid (Glu) residue in loop 1, and
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FIGURE 5 | De novo sequencing of the cyclotide caripe 8. Purity and molecular weight of caripe 8 was analyzed by (A) analytical RP-HPLC and (B) MALDI-TOF MS.
(C) The presence of the six cysteines, typical for cyclotides was confirmed via reduction and alkylation (red.+alk.) followed by MS. Cyclotide structure was elucidated
by de novo peptide sequencing, comprising the analysis of a combination of single and multiple trypsin (blue arrows, dashed line), chymotrypsin (green arrows,
dotted line) and endoproteinase GluC (endo-GluC; red arrows, solid line) digests. Tandem mass spectra of (D) an endo-GluC digest and (E) a trypsin digest are
illustrated exemplarily. The amino acid sequence was determined by manual assignment of the N-terminal b-ion and C-terminal y-ion series and the ion
fragmentation calculator tool (Data ExplorerTM, AB Sciex). (F) The full sequence was determined via sequence fragment assembly by interpretation of digest
fragments using combination of trypsin and chymotrypsin (left panel) and endo-GluC and chymotrypsin (right panel). Fragments of the different digests are indicated
by arrows. Masses labeled in the spectra refer to monoisotopic [M+H]+.
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the absence of the cis-Pro residue in loop 5, which classifies
them to the bracelet sub-family. The seven characterized
cyclotides (caripe 7, 8, 10, 11, 12, 13, psyle E) contain the
common GES motif in loop 1, the VFIP motif in loop 2
and a serine residue in loop 4 (Table 1). They significantly
differ in loops 3 and 5, which are typically recognized to
exhibit the highest sequence variability. The only differences
in loop 6 are the absence of valine in caripe 7 and caripe
13, and the presence of aspartic acid instead of asparagine
in psyle E (Table 1). Although caripe 7 and psyle E share
the same molecular weight (3254.5 Da), these cyclotides
differ in their loop 3 sequences, i.e., TVTALL (caripe 7) vs.
ISSVLG (psyle E). Similarly, caripe 8 and 13 (both have the
molecular weight 3237.4 Da), contain the sequences ITAAI
and FTSVF in loop 3, respectively. The sequence differences
of the co-eluting cyclotides of fraction C (caripe10 and 11)
and fraction D (caripe 12 and psyle E) (Figure 4) can be
found in loops 3, 5, and 6. Caripe 10 and 11 differ in
only two residues – phenylalanine vs. isoleucine (loop 3)
and lysine vs. asparagine (loop 5), respectively – resulting
in a molecular weight difference of 20 Da (Figure 4 and
Table 1). The other set of co-eluting cyclotides from fraction
D, caripe 12 and psyle E, differ by 35 Da, which is due to the
presence of phenylalanine, isoleucine (loop 3) and asparagine
(loop 6) in caripe 12, instead of isoleucine, leucine (loop 3)
and aspartic acid (loop 6) in psyle E. Following the detailed
sequence analysis of cyclotides isolated from C. ipecacuanha
that were able to modulate signaling of the CRF1R, it
was of interest to characterize this effect in pharmacological
detail.
Pharmacological Characterization of a
Novel Cyclotide Antagonist of the CRF1
Receptor
We sought to further characterize the inhibitory effect of a
purified cyclotide at the CRF1R. Based on the previous bioactivity
fractionation findings, we selected caripe 8 for subsequent
pharmacological analysis as this was the most effective inhibitor
of CRF1R-mediated luciferase activity (fraction F; Figure 3C)
relative to the other identified cyclotides. To attempt to
disambiguate the effects of cytotoxicity and non-receptor-linked
convergent signaling pathways from the previous luciferase
bioassay, we sought to examine CRF1R-mediated cAMP
accumulation. The proximal nature of cAMP generation relative
to receptor activation enables more direct assessment of CRF1R
pharmacological modulation. Similar to the luciferase assay,
caripe 8 did not exhibit any intrinsic activity in the cAMP assay.
Additionally, no effect by the cyclotide on cAMP accumulation
was observed when in combination with submaximal agonist
concentrations of forskolin. The initial titration of 2.6, 26, and
260 nM of the cyclotide with an EC50 of CRF revealed modest
concentration-dependent inhibition of CRF1R-mediated cAMP
responses (Figure 6A), and was observed to reach a threshold
(data not shown). Further exploration of this antagonism
determined a small (approximately 4.5-fold) reduction of CRF
potency by 260 nM caripe 8, but found a lack of effect on
the agonist’s maximal response (Figure 6B). In contrast, caripe
8 did not inhibit arginine-vasopressin-, or forskolin-stimulated
cAMP responses at the vasopressin V2-receptor (Supplementary
Figure 8), suggesting a CRF1R-specific mode-of-action.
TABLE 1 | Sequence alignment of cyclotides identified from Carapichea ipecacuanha.
Cyclotide Amino acid sequence† Molecular weight (Da) Identification method# Reference
Loop 1 2 3 4 5 6
Caripe 1 GVIPCGESCVFIPCIST-VIGCSCKNKVCYRN 3267.5 MS&tBLASTn Koehbach and Gruber, 2013;
Koehbach et al., 2013a
Caripe 2 G-IPCGESCVFIPCTITALLGCSCSKKVCYKN 3243.4 MS&tBLASTn Koehbach et al., 2013a
Caripe 3 XIPCGESCVFIPCISAVVGSCSC-NKVCYNN n.a.∗ tBLASTn Koehbach et al., 2013a
Caripe 4 -LICSSTCLRIPCLSPR---CTCRHHICYLN 3030.4 tBLASTn Koehbach et al., 2013a
Caripe 5 XCGESCVFIPCFTSV--GCSCKDKVCYRN n.a.∗ tBLASTn Koehbach et al., 2013a
Caripe 6 GAI-CTGTCFRNPCLSRR---CTCRHYICYLN 3199.4 tBLASTn Koehbach et al., 2013a
Caripe 7 G-IPCGESCVFIPCTVTALLGCSCKNKVCYRN 3253.3 MS&tBLASTn$ This study, Wang et al., 2008
Caripe 8 GVIPCGESCVFIPCITAAI-GCSCKKKVCYRN 3237.4 MS&tBLASTn$ This study, Wang et al., 2008
Caripe 9 XCVFIPCTITALLGCSCSNNVCYKN n.a.∗ tBLASTn$ Wang et al., 2008; Koehbach
et al., 2013a
Caripe 10 GVIPCGESCVFIPCFSTVI-GCSCKNKVCYRN 3301.3 MS This study
Caripe 11 GVIPCGESCVFIPCISTVI-GCSCKKKVCYRN 3281.3 MS This study
Caripe 12 GVIPCGESCVFIPCFSSVI-GCSCKNKVCYRN 3287.4 MS This study
Caripe 13 G-IPCGESCVFIPCFTSVF-GCSCKDKVCYRN 3237.2 MS This study
Psyle E GVIPCGESCVFIPCISSVL-GCSCKNKVCYRD 3253.4 MS This study, Gerlach et al., 2010
CYS I II III IV V IV
† Isobaric amino acids Leu/Ile were assigned based on chymotrypsin digests (see Supplementary Figures 2–7) and confirmed by amino acid analysis or based on
homology to published sequences; ∗monoisotopic masses; #the methods that were used for cyclotides characterization were mass spectrometry analysis (MS) and/or
transcriptome-mining (tBLASTn); $Cybase (Wang et al., 2008) (www.cybase.org.au) reports the precursor sequences that were identified via BLASTn from the 1 kp-project
(Koehbach et al., 2013a) (www.onekp.com); ∗not applicable, partial sequences only.
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FIGURE 6 | Caripe 8 antagonizes CRF response at the human CRF1 receptor. (A) Concentration-dependent antagonism of approximate EC80 agonist
concentrations of CRF by caripe 8. Data are mean ± SEM of three independent experiments performed in triplicate. The asterisk ‘∗’ indicates a significant difference
of caripe/CRF co-treatment as compared to CRF treatment alone (p < 0.05, One-way ANOVA with Dunnett’s post hoc test). (B) Concentration-dependent
stimulation of cAMP accumulation by CRF in the absence (closed circles) and presence of 260 nM caripe 8 (open squares) in HEK293 cells transiently expressing the
human CRF1R. Data are mean ± SEM of six independent experiments performed in triplicate. LogEC50 estimates were significantly different from each other
(p < 0.05) as determined by F test of concentration-response curve data. n.s., non-significant.
DISCUSSION
Cyclotides have been recently characterized to bind to and
activate the oxytocin- and vasopressin V1a-receptors, two
representative class A GPCRs (Koehbach et al., 2013b).
Cyclotides are widely expressed across species of flowering
plants (angiosperms) and are particularly abundant in the genus
Psychotria s.l. of the coffee-family (Rubiaceae). Therefore, in
this present study, we sought to expand our knowledge of
cyclotides as ligands of other GPCRs. In particular, we identified
and analyzed cyclotides from an ipecac root extract – a herbal
preparation that was clinically used as an expectorant or an
emetic during the past two centuries – that antagonize signaling
of the CRF1R, a prototypical class B GPCR.
Cyclotides are plant-derived cyclic peptides that are currently
of great interest as lead molecules and peptide scaffolds for
pharmaceutical drug development (Thell et al., 2016; Craik and
Du, 2017). They were first isolated from O. affinis (Rubiaceae),
a plant used as herbal preparation (‘kalata-kalata’) in traditional
Congolese medicine for its uterotonic properties (Gran, 1970;
Craik et al., 1999; Gran et al., 2000). Evidence-based proof of
the plant’s traditional use in childbirth and post-partum care was
provided in 2013; Koehbach et al. (2013b) isolated the cyclotide
kalata B7 from O. affinis and demonstrated it is a partial agonist
of the oxytocin- and vasopressin V1a-receptors. This cyclotide
exhibited only moderate affinity and potency (µM-concentration
range), probably due to the larger size of cyclotides as compared
to the endogenous neuropeptides, which likely prevents their full
penetration of the ligand-binding core of these class A GPCRs
(Koehbach and Gruber, 2013). Therefore we rationalized the
use of a representative class B GPCR in our pharmacological
screening effort, since ligand binding and activation of these
receptors involves a more open, accessible and longer N-terminal
domain (Hoare, 2005) and therefore, a larger extracellular surface
that may better accommodate interaction of the cyclotides with
the receptor.
The GPCR superfamily is the largest group of membrane
proteins in the human genome, comprising over 800 unique
GPCRs distributed throughout the human body (Fredriksson
et al., 2003). Of currently available medicines, those targeting
GPCRs represent approximately one third of all drugs, despite
comprising only 12% of all protein targets (Santos et al., 2017).
Given that only a fraction of all human GPCRs are currently
targeted, the immense potential for developing new GPCR-based
drugs thus remains substantial.
Studying and exploring the potential of plants used in
traditional medicine for the discovery of pharmacological
lead compounds has been one of the central dogmas of
ethnopharmacology and pharmacognosy (Heinrich, 2000).
Although the traditional use of ipecac has not been linked to
the corticotropin-related disorders, it is important to evaluate
any biological effects of other ingredients present in such herbal
preparations. Hence we studied the pharmacological activity
of cyclotides isolated from a root extract of C. ipecacuanha
(Rubiaceae) at the CRF1R. We utilized a robust luciferase
reporter gene assay (Koehbach et al., 2013b) together with
cells transiently expressing this receptor. The extract prepared
from Carapichea root powder itself had no effect on luciferase
induction at those cells, but it inhibited CRF-induced response
in a concentration-dependent manner (Figure 1). On the other
hand, cyclotide extracts derived from other plant species, such
as Viola tricolor did not result in any marked modulation of
CRF ligand-receptor mediated signaling (data not shown),
which provided first confidence about the presence of a specific
compound(s) in the ipecac extract with the ability to modulate
CRF1R signaling.
The existence of cyclotides in C. ipecacuanha was first reported
by Koehbach et al. (2013a). At the time we identified six
near-complete sequences of cyclotides (caripe 1 to 6) using
a combination of transcriptome-mining and de novo peptide
sequencing. Caripe cyclotides were identified in leaf as well as
root tissue of the plant (Koehbach et al., 2013a). Following
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our approach to identify novel CRF1R-modulating cyclotides,
we utilized bioassay-guided fractionation: purified cyclotide
fractions were prepared by preparative and semi-preparative
HPLC and were screened for pharmacological activity using the
luciferase reporter assays, as described above. With the support
of MALDI-TOF/TOF MS experiments the cyclotide sequence
was characterized by manual de novo peptide sequencing. From
those cyclotide-positive fractions it was possible to derive seven
cyclotide sequences and confirm their existence for the first time
at peptide level in Carapichea (summarized in Table 1). All
cyclotides isolated from C. ipecacuanha to date belonged to the
bracelet subfamily, which are characterized by the absence of
a cis-Pro residue in loop 5 (Craik et al., 1999). In agreement
with sequencing studies of other bracelet cyclotides, caripe
7, 8, 10–13 and psyle E show highest variability in loops 3
and 5 by the number and types of residues present. Loop 3
contains largely hydrophobic residues apart from a conserved
Gly, whereas as loop 5 has a conserved Val/Ile at the C-terminal
position. In addition, they all contain at least two positively
charged residues in loop 5. Previous structural studies suggested
that loop 3 exhibits the only important difference in three-
dimensional structures of the different cyclotide subfamilies. In
Möbius, exemplified by kalata B1, this four residue loop forms
a relatively disordered extended strand, but in bracelet it is
sufficiently long to form two turns of a 310-helix (Craik et al.,
1999). Therefore it may be speculated that the caripe bracelet
cyclotides also contain a helical motif, which may be important
for the observed pharmacological activity, since loop 3 is thought
to contain the GPCR modulating motif in kalata B7 (Koehbach
et al., 2013b).
All purified cyclotide fractions were tested for their potential
to inhibit CRF1R receptor signaling, and we found that cyclotide
fractions B to G had inhibitory potential with varying degrees
of apparent effectiveness. Cyclotide fraction F, containing pure
caripe 8, was the most effective antagonist, and consequently,
caripe 8 was chosen for further detailed pharmacological analysis.
Examination of the effects of caripe 8 on cAMP accumulation
revealed a much more subtle, yet CRF1R-specific, antagonism.
This modest and limited antagonism suggests that caripe 8 does
not interact competitively with the CRF binding site of the
receptor. The greater magnitude of antagonism by caripe 8 in
the luciferase assay may be either due to the cyclotide modulating
additional cellular pathways (be they CRF1R-specific or not) that
converge on the (CRE) luciferase output, or an amplification of
antagonist effect to this downstream output.
Whether the apparent CRF1R antagonizing effects of
cyclotides present in a Carapichea root extract have any
biological relevance associated with the traditional use of ipecac
preparations can only be speculative at this stage. First of all this
would require a quantitative analysis of cyclotides in various
herbal ipecac preparations, since cyclotide content depends on
the method of extraction (Farhadpour et al., 2016) as well as
the origin of the plant material and season of harvest (Trabi
et al., 2004). Secondly, the pharmacokinetic properties of caripe
cyclotides would need to be analyzed. For instance, an ipecac
preparation administered orally as an emetic, may result in very
low cyclotide uptake, if any, and hence lack of CRF1R effects.
Lastly, even if cyclotides will be successfully taken up as part
of the administration of an ipecac preparation, their CRF1R
antagonizing effects are mild and likely would not be biologically
relevant in the context of traditional use of ipecac. Regardless,
the observed receptor-specific nanomolar antagonism provides
a novel pharmacophore scaffold to develop new peptide-based
antagonists for the CRF1R.
Whilst there appears to be no overt sequence or structural
homology between the caripe cyclotides, endogenous CRF and
other known peptide antagonists (Seidel et al., 2017), unlike
previous investigation of kalata B7 (Koehbach et al., 2013b),
interrogation of linear segments of these cyclotides may yield lead
peptides with enhanced inhibitory activity of CRF1R. Without
the structural constraints of the cyclotide scaffold, the antagonist
pharmacophore may have greater flexibility to interact with
the CRF1R. Alternatively, considering the structural properties
of cyclotides, which exhibit enhanced stability and protease
resistance in comparison to linear peptides (Craik et al., 1999;
Ireland et al., 2006), our findings of a stable cyclotide ligand
of the CRF1R could thus be of relevance for future use as
a template to design new cyclotide-based GPCR ligands. This
has been successfully demonstrated with grafted cyclotide as
ligands of the melanocortin 4 receptor (Eliasen et al., 2012).
Accordingly, further modifications to the caripe peptides could
yield CRF1R antagonists with greater pharmacodynamic and
improved pharmacokinetic properties. Hence, the cyclotides
analyzed during this study from C. ipecacuanha could serve as
useful tools and templates to develop novel antagonists that target
the CRF1R.
In conclusion, we identified a cyclotide-containing plant
extract that was able to modulate the CRF1 receptor which
confirms the concept of cyclotides being a treasure trove for
drug discovery (Koehbach et al., 2013b). In fact, this is the
first time that cyclotides were reported to modulate signaling of
class B GPCRs. At a more general level, plants and their active
ingredients have always been considered as a rich source for
the preparation of herbal medicines and the discovery of novel
drugs. There are numerous examples of plant-derived chemicals
that have led to the development of important drugs such as
Aspirin R© and Taxol R©. Although small molecules, they highlight
the potential of cyclotides and other plant-derived peptides might
provide for drug discovery and development in the future.
MATERIALS AND METHODS
Peptide Extraction and Enrichment
Carapichea ipecacuanha root powder (cat. no. 66804) was
purchased from Alfred Galke GmbH (Bad Grund, Germany).
The plant material (200 g) was extracted with 1 L of
methanol/dichloromethane, 1:1 (v/v) for 18–24 h by maceration
under continuous agitation at 25◦C. After filtration 0.5 volume
of ddH2O was added to the extract, and the methanol/water
phase, which contained the cyclotides, was obtained by
liquid/liquid phase separation. This aqueous mixture was further
pre-purified by C18 solid-phase extraction. The dried, crude
extract was dissolved in 10% methanol/90% ddH2O (v/v)
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and then loaded onto C18 material ZEOprep 60 Å, irregular
40–64 µm (Zeochem, Uetikon, Switzerland) that had been
activated with methanol and equilibrated with solvent A (100%
ddH2O/0.1% trifluoroacetic acid, v/v). After washing with 10%
solvent B (90% acetonitrile/10% ddH2O/0.08% trifluoroacetic
acid, v/v/v) it was eluted with 80% solvent B to separate
the cyclotide-containing fraction from polar compounds. This
pre-purified extract, containing cyclotides, is referred to as
‘ipecac extract.’ Following initial analysis of the pre-purified
ipecac extract, cyclotides were enriched by a second cycle
of solid phase extraction including washing of the extract
with 30% solvent B and elution with 80% solvent B. The
resulting fraction is referred to as ‘cyclotide-enriched ipecac
fraction.’
Peptide Fractionation and Purification
Using Liquid Chromatography
The dried ipecac extract or cyclotide-enriched ipecac fraction
were dissolved in solvent A for liquid chromatography. The
mobile phase for all HPLC analysis and purifications consisted
of solvent A (100% ddH2O/0.1% trifluoroacetic acid, v/v) and
solvent B (90% acetonitrile/10% ddH2O/0.08% trifluoroacetic
acid, v/v/v) and separations were performed on a Dionex 3000
LC unit (Dionex, Amsterdam, The Netherlands), as published
earlier (Hellinger et al., 2015a). Analytical RP-HPLC was carried
out using a Kromasil C18 column (250 mm × 4.6 mm,
5 µm, 100 Å; dichrom GmbH, Marl, Germany) at a flow
rate of 1 mL min−1, and peptides were separated with
linear gradients of solvent B between 15 and 65% at 0.66%
min−1, including pre- and post-gradient equilibration steps.
Cyclotide fractionation and purification was performed at
preparative and semi-preparative scale using a Phenomenex
Jupiter C18 column (250 mm × 21.2 mm, 10 µm, 300 Å;
Phenomenex, Aschaffenburg, Germany) and a Kromasil C18
column (250 mm × 10 mm, 5 µm, 100 Å). The flow
rates were set to 8 and 3 mL min−1, respectively, and the
cyclotides were separated with linear gradients of solvent
B between 15 and 65% at 0.4% min−1 (preparative) and
0.57% min−1 (semi-preparative), including pre- and post-
gradient equilibration steps. Elution profile was monitored
via UV absorbance at 214, 254, and 280 nm. Cyclotide
fractions were collected manually according to their absorbance
214 nm.
Peptide Analysis Using MALDI-TOF
Mass Spectrometry
Analysis of peptide samples were performed by MS using
a MALDI-TOF/TOF 4800 Analyser (AB Sciex, Framingham,
MA, United States) operated in reflector positive ion mode
acquiring between 2000 and 10000 total shots per spectrum with
a laser intensity set between 3200 and 3800. Samples for MS
experiments were prepared using α-cyano-hydroxyl-cinnamic
acid as matrix (Sigma–Aldrich, St. Louis, MO, United States)
in ddH2O/acetonitrile/trifluoroacetic acid, 50/50/0.1% (v/v/v) at
a concentration of 5 mg mL−1. An aliquot of each sample
(0.5 µL) was mixed with of matrix solution (3 µL) and spotted
directly onto the MALDI target plate. Spectra were processed and
analyzed using the Data Explorer SoftwareTM (AB Sciex).
Reduction, Alkylation, and Enzymatic
Digest
Reduction of disulfide bonds was performed by dithiothreitol
(Sigma–Aldrich) using 2 µL of a freshly prepared 0.2 M
solution (prepared in 0.1 M NH4HCO3, pH 8.2) that was added
to 20 µL of extract, cyclotide-enriched fraction or purified
cyclotide dissolved at a concentration of 5 mg mL−1 in 0.1 M
NH4HCO3 buffer (pH 8.2). The reduction mixture was allowed
to incubate for 30 min at 37◦C. Afterward, the reduced samples
were carbamidomethylated for 10 min at 23◦C in the dark by
adding 4 µL of 100 mM iodoacetamide (prepared in 0.1 M
NH4HCO3, pH 8.2 by briefly heating to 65◦C for 1 min) to the
mixture. The alkylation reaction was stopped by adding 1 µL
of 10 mM dithiothreitol. Samples were used for MS analysis
or enzymatic digest in preparation for peptide sequencing. For
digestion the purified cyclotides (after reduction and alkylation)
was performed by adding 2 µL of trypsin, endo-GluC, or
chymotrypsin (0.1–0.5 µg µL−1, Sigma–Aldrich). All digests
were incubated at 37◦C for 3–16 h, quenched with concentrated
acetic acid (final concentration 3%) and stored at −20◦C until
further analysis.
De Novo Peptide Sequencing by Tandem
Mass Spectrometry
Tandem mass spectra were acquired using a laser energy of 1 kV,
with or without the use of collision-induced dissociation. The
spectra were examined and sequenced based on assignment of
the N-terminal b-ion and C-terminal y-ion series in combination
with automated sequence analysis using the Data Explorer
Software. The disulfide connectivity of the conserved cysteines
(CI−IV, CII−V, and CIII−VI) and the isobaric amino acid Leu and
Ile were assigned based on homology with published sequences,
and/or chymotrypsin fragmentation pattern. In addition the
amino acid compositions of novel, purified peptides (caripe 7, 8,
and 10; 100–200 µg) were confirmed with high sensitivity amino
acid analysis using gas hydrolysis (Australian Proteome Analysis
Facility, Sydney, NSW, Australia).
Cell Culture, Transfection and Functional
Luciferase Reporter Assays
HEK293 cells were co-transfected with CRF1R plasmid and firefly
luciferase containing plasmid pGL4.29 luc2P (Promega GmbH,
Mannheim, Germany) expressing the downstream DNA binding
elements of GPCR activation (CRE for Gαs-coupled signaling).
Using CaPO4 transfection (Koehbach et al., 2013b), 2.4 × 106
of HEK293 cells per 10 cm dish were prepared and cultured in
Dulbecco’s modified Eagle’s medium (PAA, Pasching, Austria)
supplemented with 10% fetal bovine serum at 37◦C with a
humidified atmosphere at 5% CO2 for 16 h. Then 6 µL of each
needed plasmid (CRF1R and CRE for Gαs-coupled signaling)
with a concentration of 1 µg µL−1, was mixed with 287.4 µL
H2O + CaCl2 (250 µL H2O + 37.4 µL CaCl2) and added
to 300 µL of HEPES-buffered saline buffer. After 20 min, the
Frontiers in Pharmacology | www.frontiersin.org 11 September 2017 | Volume 8 | Article 616
fphar-08-00616 September 21, 2017 Time: 16:33 # 12
Fahradpour et al. Isolation and GPCR Pharmacology of Ipecac Cyclotides
solution was added to the medium and the cells were incubated
for 6 h at 37◦C. Cells were then seeded into 96-well plates (5× 104
cells per well) and incubated with different concentrations of
cyclotide-enriched fractions with and without 50 nM endogenous
agonist CRF in white medium supplemented with 10% fetal calf
serum (Gibco, Gaithersburg, MD, United States) plus antibiotics.
Following 6 h of incubation at 37◦C, medium was removed
and then cells were lysed using the luciferase cell culture lysis
reagent (Promega GmbH). The luminescence and fluorescence
intensities were measured via the Synergy H4 microplate
reader (Biotek Instruments, Winooski, VM, United States). The
measured luciferase counts were corrected using the fluorescent
intensity for the number of cells per well and normalized to the
maximum activation of endogenous CRF agonist of the CRF1R.
Peptide Quantification
Molar extinction coefficients (ε at 280 nm) of novel
cyclotides were determined according to the formula
ε280 = nC∗120 + nW∗5690 + nY∗1280 [M−1 cm−1] (where
n is the number of residues). The concentration of reconstituted
purified peptides was calculated by the Beer-Lambert law based
on absorbance measurements at 280 nm using the Nanodrop
1000 (Thermo Fisher Scientific, Waltham, MA, United States).
Accordingly the molar extinction coefficient (ε280) of caripe 8
was calculated to 2000 M−1 cm−1.
cAMP Accumulation Assays
Receptor-mediated cAMP accumulation was measured in
HEK293 cells transiently transfected with the human CRF1R
(with C-terminal GFP tag) using the LANCE R© Ultra cAMP
Detection kit (PerkinElmer, Waltham, MA, United States). To
prepare for experiments, HEK293 cells were grown to confluence
in a 6-well plate, followed by transfection with 2.5 µg of plasmid
DNA per well using the Lipofectamine R© 2000 transfection
reagent (Thermo Fisher Scientific). After 4–6 h post-transfection,
the cell media was replaced, followed by dissociation of cells
via trituration and division of the cell suspension to avoid
overcrowding over the subsequent 48 h of incubation at 37◦C
and 5% CO2. On the day of assay, cells were dissociated with
phosphate buffered saline- (PBS-)EDTA solution (137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 1 mM
EDTA) and re-suspended in stimulation buffer (1.26 mM CaCl2,
0.49 mM MgCl2, 0.41 mM MgSO4, 5.33 mM KCl, 0.44 mM
KH2PO4, 4.17 mM NaHCO3, 138 mM NaCl, 0.34 mM Na2HPO4,
5.56 mM D-glucose, 5 mM HEPES, 0.5 mM IBMX, 0.1% BSA; pH
7.4). Stimulation of cAMP accumulation via the human CRF1R
and the human V2R used 500 cells and 300 cells (expressing
these receptors) per well, respectively, in 384-well white Cellstar R©
plates (Greiner Bio-One, Kremsmuenster, Austria). Cells were
incubated with the respective cognate receptor agonist peptides,
in the absence and presence of cyclotide, for 30 min at 23◦C in
a final volume of 10 µL of stimulation buffer. Termination of
cAMP accumulation was performed with the addition of 5 µL
of Eu-cAMP tracer solution and 5 µL of ULight-anti-cAMP
antibody solution, each prepared in detection buffer, followed by
incubation of the plate for 1 h at 23◦C with the lid on. After
incubation, the plate was read in a Flexstation 3 plate reader
(Molecular Devices, Sunnyvale, CA, United States).
Data Analysis and Statistics
Data from cellular assays were analyzed using GraphPad Prism
7.01 (GraphPad Software, San Diego, CA, United States).
Concentration-response curve data were fitted to the three-
parameter logistic equation to derive estimates of potency
(LogIC50, luciferase; LogEC50, cAMP) and efficacy (Emax),
relative to the maximal agonist control response. CRF LogEC50
values in the absence and presence of caripe 8 were statistically
compared via extra sum-of-squares F test analysis. Other
statistical analyses were performed as appropriate using one-way
analysis of variance (ANOVA) with Bonferroni’s post-test, and
significance taken as p< 0.05.
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